Simvastatin and asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia

Clinical Laboratory

Volumn 56, Issue 7-8, 2010, Pages 291-302

  Vladimirova Kitova, Ludmila G ^a   Deneva, Tania I ^b  

^a Department of Cardiology ^*  (Bulgaria)

^b MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

Author keywords

Asymmetric dimethylarginine; Endothelial dysfunction; Hypercholesterolemia; Low density lipoprotein cholesterol; Statins; Total homocysteine

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; SIMVASTATIN; TRIACYLGLYCEROL; ARGININE; DRUG DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LIPID; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; ARGININE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMOCYSTEINE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; SIMVASTATIN; TREATMENT OUTCOME;

EID: 77957373547     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000;101:e16-e22.
2. Favre A, Monpere C, Voyer C, et al. How to improve primary prevention in asymptomatic high risk subjects. Eur Heart J 2004;6 Suppl J:J59-63.
3. Schuster H. Under-treated high risk patients: identifying patients in high-risk subgroup and treating them to LDL targets Eur Heart J 2005;7 Suppl A:20-8.
4. Mehta JL. Statins: Understanding clinical use. W.B. Saunders Company (publisher) 2004; 163-87.
5. Davignon J. The cardioprotective effects of statins. Curr Atheroscler Rep 2004;6:27-35. (Pubitemid 38898907)
6. Laufs U, La F, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35. (Pubitemid 28152885)
7. Böger RH, Vallance P, Cooke JP. Asymmetric dimethylarginine (ADMA):a key regulator of nitric oxide synthase. Atherosclerosis 2003;4 Suppl 4:1-3. (Pubitemid 38234488)
8. Böger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003;41:1467-72. (Pubitemid 37493562)
9. Kawashima S, Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 998-1005. (Pubitemid 38737823)
10. Böger RH, Cooke JP, Vallance P. ADMA: an emerging cardiovascular risk factor. Vasc Med 2005;10:S1-2. (Pubitemid 43137261)
11. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-5. (Pubitemid 29289071)
12. Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006;38:126-36.
13. Böger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells. Circ Res 2000;87:99-105.
14. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylagrinine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998;98:1842-7. (Pubitemid 28509278)
15. Jang JJ, Ho HKV, Kwan HH, Fajardo LF, Cooke JP. Angiogenesis is impaired by hypercholesterolemia. Role of asymmetric dimethylarginine. Circulation 2000;102:1414-9.
16. Achan V, Ho HK, Heeschen C, et al. ADMA regulates angiogenesis: genetic and metabolic evidence. Vasc Med 2005;10:7-14. (Pubitemid 40667580)
17. Cooke JP. ADMA: its role in vascular disease. Vasc Med 2005;10:S11-7. (Pubitemid 43137263)
18. Ardigo D, Stuehlinger M, Franzini L, et al. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. European Journal of Clinical Investigation 2007;37:263-9. (Pubitemid 46439414)
19. Juonala M, Viikari J, Alfthan G, et al. Brachial Artery Flow-Mediated Dilation and Asymmetrical Dimethylarginine in the Cardiovascular Risk in Young Finns Study. Circulation 2007;116:1367-73. (Pubitemid 47417562)
20. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in population at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003;166:279-84. (Pubitemid 36071686)
21. Janatuinen T, Laakso J, Laaksonen R, et al. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc Med 2003;8:185-9. (Pubitemid 38220196)
22. Jiang J, Jiang D, Tang Y, Li N, Deng H, Li Y. Effect of simvastatin on endothelium-dependent vasorelaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin 2004;25:893-901. (Pubitemid 38915447)
23. Periera EC, Bertolami MC, Faludi AA, Salem M, Bersch D, Abdalla D. Effects of Simvastatin and L-Arginine on Vasodilation, Nitric Oxide Metabolites and Endogenous NOS Inhibitors in Hypercholesterolemic Subjects. Free Radical Research 2003;37:529-36. (Pubitemid 36410894)
24. Päivä H, Laakso J, Lehtimäki T, Isomustajärvi M, Ruoko I, Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003;41:219-22. (Pubitemid 36135246)
25. Valkonen VP, Laakso J, Päivä H, et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atherosclerosis 2003;4 Suppl 4:19-22. (Pubitemid 38234490)
26. Shinohara KB, Shoji T, Kimoto E, et al. Effect of Atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2005;12:205-10.
27. Bolayirli IM, Aslan M, Balci H, Altug T, Hacibekiroglu M, Seven A. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sciences 2007;81:121-7. (Pubitemid 46921173)
28. Sasaki S, Kuwahara N, Kunitomo K, et al. Effects of Atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 2002;89:386-9. (Pubitemid 34142510)
29. Lu TM, Ding YA, Leu HB. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;94:157-61.
30. Oguz A, Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 2008;49:303-11.
31. Böger RH. Asymmetric dimethylarginine (ADMA) modulates endothelial function-therapeutic implications. Vasc Med 2003;8:149-51. (Pubitemid 38220191)
32. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004;291:2821-7. (Pubitemid 38747801)
33. Kajinami K, Takekoshia N, Brousseau ME, Schaefer EJ. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004;177:219-34. (Pubitemid 39505252)
34. Martens-Lobenhoffer J, Westphal S, Awiszus F, Bode-Böger SM, Luley C. Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA? Clinical Chemistry 2005;51(11):2188-9. (Pubitemid 41532646)
35. Valtonen P, Karppi J, Nyyssönen K, Valkonen VP, Halonen K, Punnonen T. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. Journal of Chromatography B;828(1-2):97-102.
36. Vladimirova-Kitova LG, Deneva T, Angelova E, Nikolov F, Marinov B, Mateva N. Relationship of asymmetric dimethylarginine with flow-mediated dilation in subjects with newly detected severe hypercholesterolemia. Clinical Physiology and Functional Imaging 2008;28:417-25.
37. Gornic HL, Creager MA. Arginine and endothelial and vascular health. J Nutr 2004;134:2880S-7S. (Pubitemid 39315241)
38. Böger GI, Maas R, Schwedhelm E, et al. Improvement of endothelium-dependent vasodilation by simvastatin is potentiated by combination with L-arginine in patients with elevated asymmetric dimethylarginine levels. J Am Coll Cardiol 2004;43(Suppl.):525A.
39. Tsikas D, Böger RH, Sandmann J, Bode-Böger SM, Flölich JC. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 2000;478:1-3. (Pubitemid 30462247)
40. Ivashchenko CY, Bradley BT, Ao Z, Leiper J, Vallance P, Douglas JG. Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the response element binding proteins, SREBP1c and -2. Am J Physiol Heart Circ Physiol 2010;298:H251-258.
41. Ivashchenko CY, Bradley BT, Ao Z, Vallance P, Johns DG. Regulation of the ADMA-DDAH system in endothelial cells. A novel mechanism for the sterol element binding proteins, SREBP1c and SREBP2 [abstract 56]. 4th International Symposium on ADMA;2008 Aug 28-29; Bregenz, Lake Constance, Austria.
42. Horvarth AD. Mollecular heterogeneity of LDLR and Apo B genes in healthy people and in patients with hypercholesterolemia in Bulgaria. Medical University, Sofia, Bulgaria. 2001;68-69 (Thesis).
43. Horvath A, Chorbov V, Zaharova B, Ganev V. Five polymorphisms of the apolipoprotein B gene in healthy Bulgarians. Human Biology (2003);75(1):69-80. (Pubitemid 36418451)
44. Lüftjohann D, Sigit JI, Locatelli S, Bergmann K. High-dose simvastatin (80 mg/day) decreases plasma concentrations of total homocysteine in patients with hypercholesterolemia. Atherosclerosis 2001;155:265-6. (Pubitemid 32167150)
45. Jankowski P, Kawecka-Jaszcz K. Lipid-lowering drugs and homocysteine. A comparison between statins and other lipid-lowering drugs [letter]. Atherosclerosis 2004;172:191-4. (Pubitemid 38058620)
46. Miltiadous G, Papakostas J. Letter to the editor: Statins and homocysteine. Atherosclerosis 2003;166:199-200.
47. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006 Apr 17;97(8A):52C-60C.
48. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006 Apr 17;97(8A):44C-51C.
49. Blackwell S. The biochemistry, measurement, and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem 2010;47:17-28.
50. Böger GI, Rudolf TK, Renke M, et al. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilatation by simvastatin. J. Am Coll Cardiol 2007;49:2274-82. (Pubitemid 46856823)
51. Vladimirova-Kitova L, Terzieva D, Nikolov F. Asymmetric dimethylarginine determines the effect of simvastatin on endothelium- dependent vasodilation in severe hypercholesterolemia. Clin Lipidol 2010;5(1):29-41.
52. Landmesser ULF, Hornig B, Drexler H. Endothelial dysfunction in hypercholesterolemia: mechanism, pathophysiological importance, and therapeutic interventions. Seminars in Thrombosis and Hemostasis 2000;26:529-37.